Fondazione Policlinico Universitario Agostino Gemelli IRCCS — Sponsor Intelligence | 24 EU Trials

Filter these 24 trials by condition, phase, country and more.

Open in Search →

24 Registered trials

12 Recruiting

11 Completed trials

4 Countries active

57 Unique IMPs

100% Results reported

Phase II

Phase IV

Phase III: 2 Phase II: 13 Phase I/II: 2 Phase IV: 7

100%

11 of 11 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Cervical dysplasia 1 Malignant peritoneal neoplasm 1 Fallopian tube cancer 1 Depression 1 Vulvar dysplasia 1 Colorectal adenocarcinoma 1 Optic glioma 1

Top IMPs

PEMBROLIZUMAB 2 [18F]FAPI-74 1 [18F]MC225 1 AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR EXPRESSING A CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CD19 1 DOXORUBICIN HYDROCHLORIDE 1 NERVE GROWTH FACTOR, RECOMBINANT (R100E) 1 OSIMERTINIB 1 RUCAPARIB 1

All trials

24 total

MITO CERV4: Single arm phase II study on Pembrolizumab in pre neoplastic high grade HPV-related vulvar and cervical lesions Pending

2023-504035-40-00 Phase II 1 country PEMBROLIZUMAB
Hepatic radiotherapy added to standard of care for the treatment of HLA A*02:01 positive Metastatic Uveal Melanoma patients Recruiting

2024-519760-40-00 Phase II 1 country
Evaluation of p-glycoprotein alterations in treatment-resistant depression: a [18F]MC225 PET study Recruiting

2023-508303-20-01 Phase II 1 country [18F]MC225
Searching simple biomarkers to phenotype type 2 diabetic patients and personalize their treatment Recruiting

2024-516542-19-00 Phase IV 1 country
CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZE… Recruiting

2024-517789-41-00 Phase IV 1 country
PROSPECTIVE EVALUATION OF THE DDR GENES ALTERATION TO PREDICT RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED UROTHELIAL CANCER Recruiting

2024-516450-21-00 Phase IV 1 country
Anti-CD19 CAR T-Cell TherApy in Refractory Systemic Autoimmune DISeases - CATARSIS Recruiting

2024-511293-74-01 Phase I/II 1 country AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR EXPRESSING A CHIMERIC ANTIG…
Effect of proton pump inhibitors on the structural integrity of endoscopic sleeve gastroplasty: a single-centre open-label, randomized, cont… Recruiting

2024-517679-18-00 Phase IV 1 country
Indocyanine green to assess vascularity of ileal conduit anastomosis and regulate ureteral resection margins during pelvic exenteration for … Recruiting

2024-518783-13-00 Phase II 1 country
Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non… Recruiting

2024-518937-26-00 Phase II 1 country
Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy with systemic Nabpaclitaxel-Gemcitabine chemotherapy for pancreatic … Recruiting

2024-518938-81-00 Phase II 1 country
Randomized phase III trial on NIraparib-Dostarlimab vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peri… Recruiting

2024-516649-38-00 Phase III 4 countries
RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone orenzalutamide) as first-line… Recruiting

2024-518623-30-00 Phase IV 1 country
Early recognition of progressive lung fibrosis in systemic rheumatic diseases: a characterization of the pulmonary environment through extra… Ended

2024-516304-42-00 Phase II 1 country [18F]FAPI-74
ENCORAFENIB+CETUXIMAB BEYOND PROGRESSION IN COMBINATION WITH FOLFIRI IN PATIENTS WITH BRAF V600E MUTATED METASTATIC COLORECTAL CANCER PROGRE… Ended

2023-508615-24-00 Phase II 1 country
Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy. DIAMOND STUDY Ended

2024-518017-26-00 Phase II 1 country
Single-center phase II study on the use of electrochemotherapy in the treatment of Paget's disease and high-grade or initially invasive prec… Ended

2024-518796-65-00 Phase II 1 country
Safety and Efficacy of multiple doses of the PAINLESS Nerve Growth Factor CHF6467 in paediatric subjects with Optic Pathway Glioma (OPG). A … Ended

2024-515753-16-00 Phase I/II 1 country NERVE GROWTH FACTOR, RECOMBINANT (R100E)
Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2) Ended

2024-517424-18-00 Phase IV 1 country OSIMERTINIB
Single-cell deep phenotyping of B lymphocytes to personalize immunotherapy in patients with Myasthenia Gravis: clinical trial to evaluate th… Ended

2024-518939-12-00 Phase III 1 country
RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL.(REPRAB … Ended

2024-518847-40-00 Phase II 1 country DOXORUBICIN HYDROCHLORIDE
Prospective, non randomized, Phase II study on MK-3475 in recurrent, platinum-resistant, CPS ≥1 positive ovarian, Fallopian tube and primary… Ended

2024-516629-30-00 Phase II 1 country PEMBROLIZUMAB
MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucapar… Ended

2024-516632-99-00 Phase II 1 country RUCAPARIB
PROgnostic value of precision medicine in patients with Myocardial Infarction and non-obStructive coronary artEries: the PROMISE study Ended

2024-518724-72-00 Phase IV 1 country

Showing 1–24 of 24 trials

← All sponsors A–Z